Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Serina Therapeutics completed sentinel dosing in Cohort 1 of its Phase 1b registrational trial evaluating SER-252 for advanced Parkinson’s disease. Following a review of 72-hour safety data, the independent Safety Monitoring Committee recommended continued dosing, and patient enrollment is now active in the US and Australia.
Key figures
- Drug Name
- SER-252
- Phase Of Trial
- Phase 1b
- Mad cohort count
- 3
- Sad cohort count
- 5
- Mad patient count
- 48
- Sad patient count
- 40
- Prior guidance cohort1 completion
- end of the third quarter of 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.